Article Versions Notes

Gherghe M, Lazar AM, Mutuleanu M-D, Bordea CI, Ionescu S, Mihaila RI, Petroiu C, Stanciu AE. Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact? Cancers. 2023; 15(1):207. https://doi.org/10.3390/cancers15010207

Gherghe, Mirela, Alexandra Maria Lazar, Mario-Demian Mutuleanu, Cristian Ioan Bordea, Sinziana Ionescu, Raluca Ioana Mihaila, Cristina Petroiu, and Adina Elena Stanciu. 2023. "Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?" Cancers 15, no. 1: 207. https://doi.org/10.3390/cancers15010207

Gherghe, M., Lazar, A. M., Mutuleanu, M.-D., Bordea, C. I., Ionescu, S., Mihaila, R. I., Petroiu, C., & Stanciu, A. E. (2023). Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact? Cancers, 15(1), 207. https://doi.org/10.3390/cancers15010207